Furiex Pharmaceuticals, Inc. is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of partnered drug programs by advancing them through to Phase III in a cost-efficient manner.

Development programs are designed and driven by a leadership team that collectively has more than 75 years of experience in all areas of drug development. The Furiex model has proven success, with two products on the market and three compounds in development.

Furiex Pharmaceuticals has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets. The company is well-capitalized with a strong cash position and committed to sustainable growth, value creation and long-term profitability.